AllStripes Raises $50M in Series B Financing
Summary
AllStripes, a San Francisco, CA-based healthcare technology company dedicated to advancing treatments for people affected by rare diseases, raised $50m in Series B financing. The round was led by Lux Capital, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions (a Dassault Systèmes company), McKesson Ventures, and Maveron, along with angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation. The company intends to use the funds to: • develop the platform capabilities to enhance the user experience and strengthen the life sciences offerings, and • continue to invest in growing the team to support creating the playbook for rare disease research. It collaborates with various biopharmaceutical companies and other entities on real-world evidence studies, including: HemoShear Therapeutics, Inc., Orphan Disease Center at the University of Pennsylvania, Taysha Gene Therapies, Inc., UCB Biopharma SRL, and Novartis Pharma AG. One of AllStripes’ most recent partnerships with HemoShear Therapeutics aims to gather real-world evidence on patients’ medical experience with serious metabolic diseases through the Journey to Understand MMA and PA (JUMP) study.
Funding
Review available funding amount, funding date, investors, and linked company information related to AllStripes Raises $50M in Series B Financing in the interactive ISVWorld profile.